Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

DURECT, Nycomed amend POSIDUR Development and License Agreement

DURECT Corporation announced today that Nycomed and DURECT have amended the Development and License Agreement entered into between the parties in 2006 covering the development and commercialization of POSIDUR™ (also known as SABER™-Bupivacaine or OPTESIA™), an investigational drug for the treatment of post-surgical pain.

23 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

BioFlorida launches The BioFlorida Institute to create programs to improve science education

BioFlorida, the statewide trade association founded in 1997 to advance Florida’s bioscience industry, has approved a plan to launch The BioFlorida Institute, a not-for-profit foundation focused on education, professional development and industry resources. The Institute, working in partnership with BioFlorida, will create programs to improve science education and support bioscience entrepreneurs and scientists throughout the state.

19 Feb 2010

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced its financial and operational results for the year and the fourth quarter ended December 31, 2009.

19 Feb 2010

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.

19 Feb 2010

Echo Therapeutics makes significant advance in designing Symphony tCGM device

Echo Therapeutics, Inc., a company developing the needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, announced today that the Company has made a significant advance in the product design of its Symphony tCGM device and that it has developed its next generation electronic component package.

19 Feb 2010

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

Intezyne today announced the issuance of new patents that cover multiple dimensions of the Company’s revolutionary technology platform, the IVECTTM Method, in the major pharmaceutical markets of the United States, Europe, and Japan. All patents are wholly owned by Intezyne.

18 Feb 2010

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

West Pharmaceutical Services, Inc. today announced its results for the fourth quarter and full year of 2009.

18 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Study demonstrates once-a-week TB drug is as effective as daily dose

Researchers at the Council for Scientific and Industrial Research (CSIR) are one step closer to providing Tuberculosis (TB) sufferers with a once-a-week medicinal regime rather than their current daily doses.

18 Feb 2010

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

It looks more like an iPod than a medical tool. But the latest miniature ultrasound device created by Cornell biomedical engineering graduate student George K. Lewis could one day introduce a whole new level of home therapy for arthritis, injury and other painful ailments.

18 Feb 2010

New sugar-based polymer for disposing food packaging and other plastic items

Food packaging and other disposable plastic items could soon be composted at home along with organic waste thanks to a new sugar-based polymer.

17 Feb 2010

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Otonomy, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of OTO-104 in patients with Meniere's disease, a debilitating disorder of the inner ear affecting balance and hearing.

17 Feb 2010

Fourth-quarter and full-year 2009 results announced by Celsion

Celsion Corporation, a leading oncology drug development company, today announced financial results for the fourth quarter and year ended December 31, 2009. Management also highlighted the progress made in clinical trials of ThermoDox®, Celsion's heat activated liposomal encapsulation of doxorubicin, including the Company's pivotal Phase III trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer, and recurrent chest wall breast cancer.

17 Feb 2010

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Soligenix, Inc., a late-stage biotechnology company, announced today that it has received a Hong Kong patent which addresses its Lipid Polymer Micelle (LPM™) technology for the improved oral delivery of drugs. The issued Hong Kong patent, HK 1071054, entitled "Stabilized Reverse Micelle Compositions and Uses Thereof" covers lipid structures (reverse micelles) that promote the intestinal absorption of peptides and other sensitive drugs that cannot otherwise be given orally.

17 Feb 2010

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Cipher Pharmaceuticals Inc. today announced its financial and operational results for the fourth quarter and fiscal year ended December 31, 2009.

17 Feb 2010

Orexo AB reports year-end 2009 financial results

Sales of Abstral continue to show robust growth, with royalty revenues rising sharply during the fourth quarter – up threefold from the preceding quarter. Our partner, ProStrakan, launched during 2009 Abstral in UK, Germany, France, Spain and Greece, and product launches in additional markets are imminent. Sales growth confirms that there is a substantial medical requirement in the case of cancer patients suffering from breakthrough pain.

17 Feb 2010

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Obecure Ltd (http://www.obecure.com)., a subsidiary of Bio-Light Israeli Life Science Investments Ltd., announced today the execution of a licensing and clinical supply agreement with Farmaceutici Formenti SPA, the Italian Subsidiary of the Grunenthal Group.

17 Feb 2010

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Delcath Systems, Inc., which is testing its proprietary treatment system for metastatic cancers to the liver, announced today that the U.S. Food and Drug Administration ("FDA") will allow the Company to initiate an Expanded Use – Intermediate Size Population protocol for the hepatic arterial infusion of melphalan with venous filtration via the Delcath PHP System™ for patients with ocular and cutaneous melanoma metastatic to the liver.

16 Feb 2010

Three Dutch life-science sectors announce joint investment to research on personalized medicine

The Netherlands' three Top Institutes for life-science research (the BioMedical Materials program, the Center for Translational Molecular Medicine and Top Institute Pharma) today announced a joint investment of MEUR 28 on innovative research targeted at bringing personalized medicine closer to reality.

16 Feb 2010

Drug Delivery News and Research

Further Reading

DURECT, Nycomed amend POSIDUR Development and License Agreement

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioFlorida launches The BioFlorida Institute to create programs to improve science education

Nuvo Research reports net income in fourth-quarter, driven by FDA approval of Pennsaid

Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN

Echo Therapeutics makes significant advance in designing Symphony tCGM device

Intezyne announces new patents covering IVECT Method in major pharmaceutical markets

West Pharmaceutical Services reports 19.9% growth in consolidated fourth-quarter sales

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Study demonstrates once-a-week TB drug is as effective as daily dose

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

New sugar-based polymer for disposing food packaging and other plastic items

FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients

Fourth-quarter and full-year 2009 results announced by Celsion

Soligenix' LPM oral drug delivery technology receives Hong Kong patent

Cipher Pharmaceuticals announces fourth-quarter and fiscal year 2009 results

Orexo AB reports year-end 2009 financial results

Obecure enters into licensing and clinical supply agreement with Grunenthal's subsidiary for XR betahistine

Delcath Systems to initiate Expanded Access Program for melphalan in patients with metastatic melanoma to the liver

Three Dutch life-science sectors announce joint investment to research on personalized medicine

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News